336 related articles for article (PubMed ID: 24633422)
61. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
Mansfield AS; Murphy SJ; Harris FR; Robinson SI; Marks RS; Johnson SH; Smadbeck JB; Halling GC; Yi ES; Wigle D; Vasmatzis G; Jen J
Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
[TBL] [Abstract][Full Text] [Related]
62. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
[TBL] [Abstract][Full Text] [Related]
63.
Ross JS; Ali SM; Fasan O; Block J; Pal S; Elvin JA; Schrock AB; Suh J; Nozad S; Kim S; Jeong Lee H; Sheehan CE; Jones DM; Vergilio JA; Ramkissoon S; Severson E; Daniel S; Fabrizio D; Frampton G; Miller VA; Stephens PJ; Gay LM
Oncologist; 2017 Dec; 22(12):1444-1450. PubMed ID: 29079636
[TBL] [Abstract][Full Text] [Related]
64. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
[TBL] [Abstract][Full Text] [Related]
65. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR
Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099
[TBL] [Abstract][Full Text] [Related]
66. Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.
Saber A; van der Wekken AJ; Kok K; Terpstra MM; Bosman LJ; Mastik MF; Timens W; Schuuring E; Hiltermann TJ; Groen HJ; van den Berg A
PLoS One; 2016; 11(4):e0153065. PubMed ID: 27045755
[TBL] [Abstract][Full Text] [Related]
67. Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma".
Jara SM; Bhatnagar R; Guan H; Gocke CD; Ali SZ; Tufano RP
Head Neck; 2015 Dec; 37(12):1788-93. PubMed ID: 24989827
[TBL] [Abstract][Full Text] [Related]
68. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.
Barbaro D; Incensati RM; Materazzi G; Boni G; Grosso M; Panicucci E; Lapi P; Pasquini C; Miccoli P
Endocrine; 2014 Apr; 45(3):462-8. PubMed ID: 23925579
[TBL] [Abstract][Full Text] [Related]
69. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
[TBL] [Abstract][Full Text] [Related]
70. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
Liu C; Chen T; Liu Z
World J Surg Oncol; 2016 Sep; 14(1):241. PubMed ID: 27600854
[TBL] [Abstract][Full Text] [Related]
71. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
[TBL] [Abstract][Full Text] [Related]
72. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
[TBL] [Abstract][Full Text] [Related]
73. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
Casaluce F; Sgambato A; Maione P; Rossi A; Ferrara C; Napolitano A; Palazzolo G; Ciardiello F; Gridelli C
Target Oncol; 2013 Mar; 8(1):55-67. PubMed ID: 23325296
[TBL] [Abstract][Full Text] [Related]
74. Clinical response to crizotinib retreatment after acquisition of drug resistance.
Matsuoka H; Kurata T; Okamoto I; Kaneda H; Tanaka K; Nakagawa K
J Clin Oncol; 2013 Jul; 31(19):e322-3. PubMed ID: 23715571
[No Abstract] [Full Text] [Related]
75. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.
Sang J; Acquaviva J; Friedland JC; Smith DL; Sequeira M; Zhang C; Jiang Q; Xue L; Lovly CM; Jimenez JP; Shaw AT; Doebele RC; He S; Bates RC; Camidge DR; Morris SW; El-Hariry I; Proia DA
Cancer Discov; 2013 Apr; 3(4):430-43. PubMed ID: 23533265
[TBL] [Abstract][Full Text] [Related]
76. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
77. BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma.
Henke LE; Pfeifer JD; Ma C; Perkins SM; DeWees T; El-Mofty S; Moley JF; Nussenbaum B; Haughey BH; Baranski TJ; Schwarz JK; Grigsby PW
Cancer Med; 2015 Jun; 4(6):791-9. PubMed ID: 25712893
[TBL] [Abstract][Full Text] [Related]
78.
Bastos AU; de Jesus AC; Cerutti JM
Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
[TBL] [Abstract][Full Text] [Related]
79. BRAF mutation in fine-needle aspiration specimens as a potential predictor for persistence/recurrence in patients with classical papillary thyroid carcinoma larger than 10 mm at a BRAF mutation prevalent area.
Moon HJ; Kim EK; Chung WY; Shin DY; Kwak JY
Head Neck; 2015 Oct; 37(10):1432-8. PubMed ID: 24838814
[TBL] [Abstract][Full Text] [Related]
80. AGK-BRAF gene fusion is a recurrent event in sporadic pediatric thyroid carcinoma.
Cordioli MI; Moraes L; Carvalheira G; Sisdelli L; Alves MT; Delcelo R; Monte O; Longui CA; Cury AN; Cerutti JM
Cancer Med; 2016 Jul; 5(7):1535-41. PubMed ID: 27037835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
